Elsevier

Blood Reviews

Volume 5, Issue 1, March 1991, Pages 29-37
Blood Reviews

State of the art: The hypereosinophilic syndromes

https://doi.org/10.1016/0268-960X(91)90005-WGet rights and content

Abstract

Many disease states such as parasitic infestations, malignancies, collagen vascular diseases, and allergies are associated with eosinophilia. The diagnosis of idiopathic hypereosinophilic syndrome (HES) requires a persistent elevation in the total eosinophil count (> 1500/mm3) for over 6 months, associated organ damage and no detectable underlying cause. This review provides an updated summary of the cytokine cascade that controls eosinophil production and delineates our current understanding of the clinical features of hypereosinophilic states. We also examine the central role of T-lymphocyte activation in eosinophilia, and have attempted to integrate current treatment strategies for HES with the physiology of eosinophilopoiesis.

References (103)

  • M.M. LeBeau et al.

    Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemia with a Del (5q)

    Blood

    (1989)
  • R.T Schooley et al.

    A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations

    Blood

    (1981)
  • JS Weingarten et al.

    Eosinophilic meningitis and the hypereosinophilic syndrome. Case report and review of the literature

    American Journal of Medicine

    (1985)
  • V Najfeld et al.

    Trisomy 22—A new abnormality found in acute leukemia characterized by eosinophilia and monocytoid blasts expressing immature differentiation antigens

    Cancer Genetics and Cytogenetics

    (1986)
  • A Broustet et al.

    Acute eosinophilic leukemia with a translocation (10p+;11q−)

    Cancer Genetics and Cytogenetics

    (1986)
  • A.E. Butterworth et al.

    Current concepts. Eosinophil function

    New England Journal of Medicine

    (1981)
  • M.T. Flannery et al.

    A case of the eosinophilia-myalgia syndrome associated with use of an L-tryptophan product

    Annals of Internal Medicine

    (1990)
  • A.A.F. Mahmoud

    Eosinophilopoiesis

  • D Zucker-Franklin

    Eosinophils: morphology, production, chemistry and function

  • A Slungaard et al.

    Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium

    Journal of Experimental Medicine

    (1985)
  • A.J. Wardlaw et al.

    Platelet activating factor: A potent chemotactic and chemokinetics factor for human eosinophils

    Journal of Clinical Investigation

    (1986)
  • J.M Wang et al.

    Recombinant human interleukin 5 is a selective eosinophil chemoattractant

    European Journal of Immunology

    (1989)
  • J-F Moreau et al.

    Characterization of a factor produced by human T-cell clones exhibiting eosinophil-activating and burst-promoting activities

    Journal of Immunology

    (1987)
  • Y Sonoda et al.

    Humoral regulation of eosinophilopoiesis in vitro: analysis of the targets of interleukin-3, granulocyte/macrophage colony-stimulating factor (GM-CSF), and interleukin 5

    Leukemia

    (1989)
  • D.J. Warren et al.

    Synergism among interleukin 1, interleukin 3, and interleukin 5 in the production of eosinophils from primitive hemopoietic stem cells

    Journal of Immunology

    (1988)
  • A.B. Kay

    Functions of the eosinophil leukocyte

    British Journal of Haematology

    (1976)
  • M.J. Chusid et al.

    The hypereosinophilic syndrome: analysis of 14 cases with review of the literature

    Medicine

    (1975)
  • I Winqvist et al.

    Altered density, metabolism, and surface receptors of eosinophils in eosinophilia

    Immunology

    (1982)
  • A Hartnell et al.

    Fegamma and CD11CD18 receptor expression on normal density and low density human eosinophils

    Immunology

    (1990)
  • J.R. David et al.

    Enhanced helminthotoxic capacity of eosinophils from patients with eosinophilia

    New England Journal of Medicine

    (1980)
  • L Prin et al.

    Heterogeneity of human peripheral blood eosinophils: Variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophila

    International Archives of Allergy and Applied Immunology

    (1983)
  • W.R. Henderson et al.

    Hypereosinophilic syndrome human eosinophil degranulation induced by soluble and particulate stimuli

    British Journal of Haematology

    (1988)
  • D.S. Silberstein et al.

    Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony stimulating factor

    Journal of Immunology

    (1986)
  • W.F. Owen et al.

    Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts

    Journal of Experimental Medicine

    (1987)
  • M.E Rothenberg et al.

    Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3

    Journal of Clinical Investigation

    (1988)
  • Y Yamaguchi et al.

    Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor

    Journal of Experimental Medicine

    (1988)
  • A.F. Lopez et al.

    Recombinant human interleukin 5 is a selective activator of human eosinophil function

    Journal of Experimental Medicine

    (1988)
  • G Kimani et al.

    Stimulation of eosinophil adherence to human vascular endothelial cells in vitro by platelet-activating factor

    Journal of Immunology

    (1988)
  • M.E. Rothenberg et al.

    Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor

    Journal of Cellular Biochemistry

    (1988)
  • W.F. Owen et al.

    Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome

    Journal of Experimental Medicine

    (1989)
  • A Basten et al.

    Mechanism of eosinophilia II. Role of the lymphocyte

    Journal of Experimental Medicine

    (1970)
  • D.R. Lucey et al.

    Mature human eosinophils have the capacity to express HLA-DR

  • H Enokihara et al.

    Specific production of eosinophil colony stimulating factor from sensitized T-cells from a patient with allergic eosinophilia

    British Journal of Haematology

    (1985)
  • H Enokihara et al.

    Interleukin 2 stimulates the T cells from patients with eosinophilia to produce CFU-Eo growth stimulating factor

    British Journal of Haematology

    (1988)
  • A Raghavachar et al.

    T lymphocyte control of human eosinophilic granulopoiesis

    Journal of Immunology

    (1987)
  • D.S. Silberstein et al.

    Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells

    J Immunol

    (1989)
  • P Kern et al.

    Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution

    Blut

    (1986)
  • A.A. Ythier et al.

    Interleukin-2-dependent release of interleukin-3 activity by T4+ human T-cell clones

  • Y Yamaguchi et al.

    Role of IL-5 in IL-2 induced eosinophilia: in vivo and in vitro expression of IL-5 mRNA by IL-2

    Journal of Immunology

    (1990)
  • C.J. Sanderson

    The biological role of interleukin 5

    International Journal of Cell Cloning

    (1990)
  • Cited by (33)

    • Blood eosinophilia: A new paradigm in disease classification, diagnosis, and treatment

      2005, Mayo Clinic Proceedings
      Citation Excerpt :

      For now, HES is considered a subcategory of idiopathic eosinophilia that requires documentation of both target organ damage and an AEC of 1500 cells/µL or greater for at least 6 months.20,86 Several review articles have described the clinical manifestations and natural history of HES.20,86–88 These and other case reports have shown that some cases evolve into either acute leukemia or an aggressive disease phenotype that is indistinguishable from an MPD.89–91

    • Eosinophilia in aids

      1997, Immunology and Allergy Clinics of North America
    • Cough, shortness of breath, and eosinophilia in a 68-year-old man

      1996, Annals of Allergy, Asthma and Immunology
    View all citing articles on Scopus
    View full text